|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Bausch Health Companies insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Bausch Health Companies insider buys are important for investors to follow.
Date | Insider | Price | Amount |
11-30-2021 Insider Buy |
Steven D. Miller Director |
$24.23
CAGR »
|
$1,453,524.00 60,000 shares |
8-5-2021 Insider Buy |
Andrew C. Von Eschenbach Director |
$25.94
CAGR »
|
$36,316.00 1,400 shares |
8-4-2021 Insider Buy |
Richard U. De Schutter Director |
$25.01
CAGR »
|
$250,123.00 10,000 shares |
6-5-2020 Insider Buy |
ValueAct Holdings, L.P. Director |
$19.24
CAGR »
|
$18,246,311.72 948,353 shares |
3-12-2020 Insider Buy |
Thomas W. Ross Sr. Director |
$15.54
CAGR »
|
$38,837.50 2,500 shares |
3-10-2020 Insider Buy |
Richard U. De Schutter Director |
$21.00
CAGR »
|
$184,792.36 8,800 shares |
3-10-2020 Insider Buy |
Andrew C. Von Eschenbach Director |
$18.18
CAGR »
|
$19,996.35 1,100 shares |
3-10-2020 Insider Buy |
Christina Ackermann EVP AND GENERAL COUNSEL |
$18.25
CAGR »
|
$80,105.65 4,390 shares |
9-13-2019 Insider Buy |
Joseph C. Papa CHAIRMAN & CEO |
$23.31
CAGR »
|
$699,300.00 30,000 shares |
8-16-2019 Insider Buy |
William D. Humphries President, Ortho-Dermatologics |
$21.18
CAGR »
|
$650,142.17 30,703 shares |
2-28-2019 Insider Buy |
Joseph C. Papa CHAIRMAN & CEO |
$23.67
CAGR »
|
$710,100.00 30,000 shares |
12-14-2018 Insider Buy |
Thomas Appio Pres&Co-Head Bausch&Lomb/Int'l |
$22.96
CAGR »
|
$584,018.45 25,440 shares |
9-14-2018 Insider Buy |
Joseph C. Papa CHAIRMAN & CEO |
$22.32
CAGR »
|
$669,600.00 30,000 shares |
9-14-2018 Insider Buy |
Paul Herendeen EVP and CFO |
$22.61
CAGR »
|
$226,100.00 10,000 shares |
9-13-2018 Insider Buy |
Richard U. De Schutter Director |
$23.96
CAGR »
|
$2,995,000.00 125,000 shares |
Also See: Institutional Holders of BHC
Also See: SEC filings
Below we present the annualized performance delivered by Bausch Health Companies stock since 11-30-2021 (the date of the most recent
insider purchase). The performance of the investment from the time Bausch Health Companies insider buying occurred is the ultimate
test of whether insiders were right about BHC being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/01/2021 |
|
End date: |
05/01/2024 |
|
Start price/share: |
$23.00 |
|
End price/share: |
$8.75 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-61.96% |
|
Average Annual Total Return: |
-32.99% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,804.99 |
|
Years: |
2.41 |
|
Bausch Health Companies Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Bausch Health Companies insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding BHC
|
|